Financial Performance - The company's operating revenue for Q3 2022 was ¥194,524,452.56, a decrease of 11.04% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2022 was ¥16,521,841.90, down 30.81% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥14,750,114.65, reflecting a decline of 38.52% compared to the previous year[4] - Total operating costs decreased from ¥592,743,896.16 to ¥557,743,368.96, a reduction of approximately 5.9%[18] - Net profit attributable to shareholders decreased from ¥65,251,454.52 to ¥60,333,857.59, a decline of about 7.5%[19] - Operating profit decreased from ¥88,409,326.92 to ¥77,426,756.64, a drop of approximately 12.3%[18] - Total comprehensive income decreased from ¥74,375,675.38 to ¥65,887,086.43, a decrease of about 11.5%[19] - Basic and diluted earnings per share decreased from ¥0.1972 to ¥0.1823, a decline of approximately 7.5%[19] Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date period was ¥87,206,481.59, a significant decrease of 46.50% year-on-year[4] - Cash flow from operating activities decreased from ¥163,004,140.39 to ¥87,206,481.59, a decline of about 46.6%[21] - The company's cash and cash equivalents increased by 32.00% to ¥289,992,896.36 due to improved cash flow from operations[8] - Cash and cash equivalents at the end of the period increased to ¥289,992,896.36 from ¥283,417,266.80, an increase of approximately 2.0%[22] - Net cash flow from financing activities showed a net outflow of ¥20,344,523.90 compared to a net outflow of ¥65,898,484.84 in the previous period[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,892,384,151.53, an increase of 0.98% from the end of the previous year[5] - The total assets of the company as of September 30, 2022, amounted to RMB 2,892,384,151.53, up from RMB 2,864,366,655.13 at the start of the year[15] - The total liabilities decreased slightly to RMB 665,388,413.79 from RMB 666,082,205.82, showing a marginal reduction[15] - The company's total equity increased to RMB 2,226,995,737.74 from RMB 2,198,284,449.31, reflecting an increase of approximately 1.3%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,907[10] - The top shareholder, Zhang Yisheng, holds 39.08% of the shares, amounting to 129,348,530 shares[10] Government Subsidies and Non-Recurring Gains - The company received government subsidies amounting to ¥2,314,073.95 during the reporting period, contributing to its non-recurring gains[6] Operational Metrics - Sales revenue from goods and services received cash decreased from ¥769,868,721.37 to ¥685,040,384.37, a decline of approximately 11.0%[20] - Research and development expenses increased from ¥14,891,356.12 to ¥15,482,990.67, an increase of about 3.9%[18] - Accounts receivable rose to RMB 216,225,964.18 from RMB 195,846,007.45, indicating an increase of about 10%[14] - The inventory level remained stable at RMB 1,602,331,661.55, compared to RMB 1,596,871,561.48 at the beginning of the year[14] Corporate Governance - The company is implementing a rectification plan to address issues related to shareholding disclosure, with certain shareholders no longer having shareholding proxies[12] - The company aims to resolve the shareholding proxy issues in the shortest time possible while considering the impact on the secondary market[12] Employee Compensation - The company reported a decrease in employee compensation liabilities to RMB 5,706,420.52 from RMB 7,907,392.07, indicating a reduction of approximately 28%[15]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥428,409,146.26, a decrease of 5.82% compared to ¥454,884,074.49 in the same period last year[25]. - The net profit attributable to shareholders of the listed company was ¥43,812,015.69, an increase of 5.90% from ¥41,371,047.86 year-on-year[25]. - The net cash flow from operating activities decreased by 39.79% to ¥72,426,598.89 from ¥120,294,568.26 in the previous year[25]. - The basic earnings per share increased to ¥0.1324, up 5.92% from ¥0.1250 in the same period last year[25]. - The company reported a decrease of 8.53% in net profit after deducting non-recurring gains and losses, totaling ¥32,817,432.17 compared to ¥35,876,286.87 in the previous year[25]. - The company's total revenue for the reporting period was ¥428,409,146.26, representing a decrease of 5.82% compared to the previous year[47]. - The pharmaceutical sector accounted for 82.01% of total revenue, with a year-on-year increase of 5.50% in this segment[48]. - The total profit for the first half of 2022 was CNY 87,892,527.35, compared to CNY 85,417,906.33 in the previous year, an increase of 2.9%[136]. - The company reported a net increase in cash and cash equivalents of ¥61,534,961.32 for the first half of 2022, contrasting with a decrease of ¥147,545,647.58 in the same period of 2021[142]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,888,592,843.66, reflecting a 0.85% increase from ¥2,864,366,655.13 at the end of the previous year[25]. - The company's total assets as of June 30, 2022, were CNY 2,974,259,795.98, an increase from CNY 2,935,747,364.14 at the beginning of the year[129]. - The total liabilities decreased to CNY 865,192,174.31 from CNY 898,658,750.33 at the start of the year[129]. - The inventory level was ¥1,586,034,217.18, accounting for 54.91% of total assets, showing a slight decrease from the previous year[54]. Research and Development - The company has developed 11 dosage forms and 117 varieties, with 49 products included in the National Basic Medical Insurance Drug List[38]. - The company holds 19 invention patents, 5 design patents, and 4 utility model patents, indicating a strong focus on innovation[45]. - Research and development expenses decreased by 36.99% to ¥13,327,785.79, primarily due to reduced clinical trial costs[47]. - The company has initiated research and development for new technologies aimed at enhancing product offerings[145]. - The company is focusing on enhancing its research and development capabilities to innovate new technologies and products[150]. Market and Business Strategy - The company is expanding its business model to include health foods and cosmetics, forming a complete ginseng industry chain[37]. - The company aims to leverage technological innovation and internal management to ensure sustainable development amidst a challenging market environment[33]. - The company plans to maintain its strategy of building a complete ginseng industry chain, increasing its ginseng reserves through self-cultivation and external procurement[64]. - Future guidance indicates a cautious outlook, with expectations of gradual recovery in revenue growth[145]. Social Responsibility and Governance - The company emphasizes social responsibility, focusing on environmental friendliness, resource conservation, and participation in social welfare activities[76]. - The company has implemented strict internal control systems to protect the rights of shareholders and creditors, ensuring timely disclosure of major information[77]. - The company has established a comprehensive emergency response mechanism for environmental pollution incidents, including a specific emergency plan and regular employee training[75]. - The company has not received any administrative penalties for environmental issues during the reporting period[74]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 28,525[108]. - Zhang Yisheng holds 39.08% of the shares, totaling 129,348,530 shares[108]. - The total number of shares is 330,951,600, with 69.91% being unrestricted shares[106]. - There were no changes in the number of shares held by major shareholders during the reporting period[108]. Cash Flow and Financing - The total cash inflow from operating activities was ¥390,266,026.16, while cash outflow was ¥382,315,619.37, resulting in a positive net cash flow[140]. - The company received ¥170,000,000.00 from borrowings, while cash outflow for debt repayment was ¥170,000,000.00, leading to a net cash flow from financing activities of -¥7,331,676.21[142]. - The cash flow from financing activities showed a significant decrease in cash outflow for dividend distribution, which was ¥7,265,076.21 compared to ¥16,709,623.72 in the previous year[142]. Compliance and Accounting - The financial statements are prepared based on the going concern assumption and comply with the relevant accounting standards[159]. - The company has not identified any significant doubts regarding its ability to continue as a going concern for at least 12 months from the reporting date[160]. - The financial report was approved by the board on August 25, 2022[158]. - The company adheres to the accounting policies and estimates as per the relevant accounting standards[161].

Financial Performance - The company's revenue for Q1 2022 was ¥225,540,617.25, a decrease of 1.55% compared to ¥229,097,736.43 in the same period last year[4] - Net profit attributable to shareholders was ¥27,229,639.30, down 1.93% from ¥27,765,054.54 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥19,705,067.74, representing a decline of 15.81% from ¥23,405,772.17 in the previous year[4] - Total operating revenue for the current period is $225.54 million, a decrease of 1.23% from $229.10 million in the previous period[21] - Operating profit decreased to $33.67 million, down 19.73% from $41.91 million in the previous period[22] - Net profit for the current period is $29.23 million, a decline of 12.93% compared to $33.19 million in the previous period[22] Cash Flow and Liquidity - The net cash flow from operating activities increased by 32.73% to ¥38,973,399.49, compared to ¥29,363,113.24 in the same period last year[4] - Cash flow from operating activities increased to $38.97 million, up 32.73% from $29.36 million in the previous period[26] - Cash and cash equivalents at the end of the quarter were CNY 200,989,827.14, down from CNY 219,695,016.40[17] - Cash and cash equivalents at the end of the period decreased to $200.99 million, down from $290.24 million in the previous period[27] - The company reported a net cash outflow from financing activities of $31.03 million, compared to an outflow of $12.24 million in the previous period[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,850,618,838.70, a decrease of 0.48% from ¥2,864,366,655.13 at the end of the previous year[4] - The company's current assets totaled CNY 2,208,310,379.88, slightly down from CNY 2,221,792,551.02 at the start of the year[17] - The total liabilities decreased to CNY 650,352,779.13 from CNY 666,082,205.82[19] - The company's equity attributable to shareholders increased to CNY 2,109,039,378.83 from CNY 2,081,809,739.53[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 36,823[10] - Basic and diluted earnings per share decreased to $0.0823, down from $0.0839 in the previous period[23] Expenses - Total operating costs increased to $199.83 million, up 2.03% from $194.43 million in the previous period[21] - Financial expenses rose by 98.56% to ¥2,610,477.73, primarily due to decreased interest income and increased interest expenses[8] - Financial expenses increased to $2.61 million, up from $1.31 million in the previous period[22] - Research and development expenses for the current period were $4.34 million, a decrease of 10% from $4.82 million in the previous period[21] Government Support - The company received government subsidies amounting to ¥8,400,380.57 during the reporting period[6] Accounts Receivable and Inventory - The company's accounts receivable increased by 61.76% to ¥2,922,425.05, influenced by an increase in commercial acceptance bills[8] - Accounts receivable rose to CNY 223,010,062.92 from CNY 195,846,007.45, indicating a growth of approximately 13.8%[17] - Inventory levels were reported at CNY 1,593,579,012.74, a slight decrease from CNY 1,596,871,561.48[17] Other Information - The company is addressing issues related to shareholding transparency and has implemented a plan to rectify the situation regarding shareholding disclosures[13] - The company’s short-term borrowings remained stable at CNY 397,864,988.96, compared to CNY 397,862,867.43 at the beginning of the year[18] - The company’s net profit for the first quarter of 2022 is not explicitly stated in the provided documents, but the focus on product inclusion in COVID-19 treatment guidelines suggests potential revenue growth opportunities[14]

Financial Performance - The company's operating revenue for 2021 was CNY 877,929,541.89, representing a 4.19% increase compared to CNY 842,589,907.04 in 2020[19] - The net profit attributable to shareholders for 2021 was CNY 96,020,349.90, a 19.94% increase from CNY 80,060,085.80 in 2020[19] - The net profit after deducting non-recurring gains and losses was CNY 83,970,880.18, up 27.72% from CNY 65,746,181.53 in 2020[19] - The basic earnings per share for 2021 was CNY 0.2901, reflecting a 19.93% increase from CNY 0.2419 in 2020[19] - The total assets at the end of 2021 were CNY 2,864,366,655.13, a 2.44% increase from CNY 2,796,099,005.75 at the end of 2020[19] - The net assets attributable to shareholders at the end of 2021 were CNY 2,081,809,739.53, up 4.31% from CNY 1,995,717,937.63 at the end of 2020[19] - The net cash flow from operating activities for 2021 was CNY 215,100,714.73, a 5.69% increase from CNY 203,514,966.83 in 2020[19] - The weighted average return on equity for 2021 was 4.72%, an increase from 4.08% in 2020[19] Product Development and Innovation - The company has developed a complete industrial chain for ginseng, expanding from pharmaceutical production to health products and cosmetics[31] - The company holds 117 product varieties and has 49 products listed in the National Basic Medical Insurance Drug Catalog[31] - The company has cultivated over 10,000 acres of organic non-forest ginseng, recognized as a protected ecological origin product[32] - The company has received 14 patents and established a comprehensive planting technology system for ginseng cultivation[32] - The company completed the development and filing of 30 health food products, launching 5 new products during the reporting period[42] - The company launched 14 new cosmetic products and enhanced its online sales channels, including live streaming sales[44] Market and Sales Performance - The pharmaceutical sector contributed ¥665,013,635.04, accounting for 75.75% of total revenue, with a year-on-year growth of 3.46%[46] - The online direct sales model saw a significant decline of 63.76%, dropping to ¥11,223,826.07 from ¥30,973,020.78 in the previous year[46] - The company sold 37,040,371 boxes in the pharmaceutical sector, an increase of 3.27% from 35,868,297 boxes in 2020[49] - The revenue from the cosmetics sector was ¥116,288,065.52, with a slight increase of 0.28% year-on-year[46] Research and Development - Research and development expenses increased by 32.98% to ¥20,892,630.06, primarily due to increased clinical trial costs[58] - The total R&D investment reached ¥37,584,947.77, a 13.12% increase compared to the previous year, with R&D expenses accounting for 4.28% of operating revenue[60] - The company has ongoing clinical research projects aimed at enhancing product competitiveness in the market[59] Corporate Governance and Management - The company adheres to strict governance practices, ensuring compliance with relevant laws and regulations while maintaining effective communication with shareholders[86] - The company has established a performance-based incentive and evaluation system for its senior management to align compensation with company performance[87] - The company has a robust organizational structure, with independent operation of the shareholders' meeting, board of directors, and supervisory board[91] - The company has established a performance appraisal system linking employee salaries to company performance and individual contributions[119] Social Responsibility and Environmental Compliance - The company actively engaged in social responsibility initiatives during the COVID-19 pandemic, including donations and compliance with information disclosure[45] - The company emphasizes environmental protection and has integrated energy conservation and emission reduction into its key agenda[137] - The company has not faced any administrative penalties for environmental issues during the reporting period, demonstrating compliance with environmental regulations[133] Future Outlook and Strategic Plans - The company plans to strengthen its marketing network and optimize its marketing organization to enhance overall performance in 2022[78] - The company aims to leverage existing resources through contract manufacturing to transition products from reserve to market-ready[78] - The company plans to continue expanding its market presence and product offerings in the future[114] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million yuan allocated for potential deals[104] Shareholder Structure and Transparency - The company’s shareholder structure remained stable, with no significant changes in asset and liability structure reported[173] - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[175] - The company has a total of 132,792,449 shares held by its directors and senior management, with some changes in shareholding during the reporting period[95] - The company is implementing a rectification plan to resolve the proxy shareholding issue, aiming for a swift resolution[178]

Financial Performance - The company's revenue for Q3 2021 was ¥218,657,311.81, representing a year-on-year increase of 0.71%[4] - The net profit attributable to shareholders for Q3 2021 was ¥23,880,406.66, an increase of 11.88% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥23,991,300.85, up 56.76% year-on-year[4] - Total operating revenue for Q3 2021 reached CNY 673,541,386.30, an increase of 9.7% compared to CNY 614,016,426.03 in the same period last year[20] - Operating profit for the period was CNY 88,409,326.92, up from CNY 77,844,776.38, reflecting a growth of 13.4% year-over-year[22] - Net profit attributable to the parent company was CNY 65,251,454.52, representing a 20.4% increase from CNY 54,188,768.07 in the previous year[22] - The company reported a basic earnings per share of CNY 0.1972, compared to CNY 0.1637 in the same quarter last year, marking a 20.4% increase[23] - The basic earnings per share for Q3 2021 was ¥0.0722, an increase of 11.94% compared to the same period last year[4] Cash Flow - The cash flow from operating activities for the year-to-date period reached ¥163,004,140.39, reflecting a significant increase of 101.25%[4] - The net cash flow from operating activities for Q3 2021 was ¥163,004,140.39, a significant increase of 101.01% compared to ¥80,995,109.69 in Q3 2020[26] - Cash inflow from operating activities totaled CNY 823,066,466.86, an increase from CNY 698,939,437.12 in the previous year, indicating a growth of 17.8%[24] - Cash outflows related to operating activities totaled ¥660,062,326.47, an increase of 6.73% from ¥617,944,327.43 in Q3 2020[26] - The net cash flow from investing activities was -¥100,684,903.68, a decline from -¥5,049,230.35 in the same period last year, indicating increased investment outflows[26] - Cash inflows from financing activities totaled ¥397,450,000.00, while cash outflows were ¥463,348,484.84, resulting in a net cash flow of -¥65,898,484.84 for Q3 2021[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,782,434,606.37, a decrease of 0.49% from the end of the previous year[4] - The company's total current assets as of September 30, 2021, amount to ¥2,166,911,877.68, a decrease from ¥2,223,356,178.91 at the end of 2020[18] - The total assets of the company as of September 30, 2021, are ¥2,782,434,606.37, slightly down from ¥2,796,099,005.75 at the end of 2020[18] - Total liabilities amounted to CNY 614,470,617.15, a decrease from CNY 663,864,893.91 at the end of the previous period[20] - Total liabilities stood at ¥663,864,893.91, remaining consistent with the previous year, which suggests effective liability management[31] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,677[12] - Zhang Yisheng holds 39.08% of shares, totaling 129,348,530 shares, with 97,011,397 shares under lock-up conditions[12] - The company's equity attributable to shareholders increased by 2.77% to ¥2,051,040,844.15 compared to the end of the previous year[4] - The company's equity attributable to shareholders was ¥1,995,717,937.63, reflecting stability in shareholder value compared to the previous year[31] Investment and Development - The company reported a significant increase of 246.56% in construction in progress, amounting to ¥93,827,462.31, due to increased investment in the cosmetics deep processing industry project[9] - Research and development expenses for the quarter were CNY 14,891,356.12, slightly up from CNY 14,423,381.56, indicating continued investment in innovation[20] - The company has ongoing discussions regarding potential market expansion and new product development strategies[13] Financial Management - Financial expenses decreased by 41.90% to ¥4,482,915.62, primarily due to increased interest from agreement deposits[9] - The company has adopted new leasing standards starting in 2021, which may impact future financial reporting and asset management strategies[28] - The third quarter report for 2021 was not audited, which may affect the reliability of the financial data presented[32] Inventory and Receivables - The company's inventory as of September 30, 2021, is ¥1,609,706,267.63, compared to ¥1,615,762,224.99 at the end of 2020[18] - The company reported accounts receivable of ¥207,843,199.78 as of September 30, 2021, up from ¥205,229,958.10 at the end of 2020[18]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 454,884,074.49, representing a 14.61% increase compared to CNY 396,894,638.67 in the same period last year[23]. - The net profit attributable to shareholders was CNY 41,371,047.86, which is a 25.96% increase from CNY 32,843,900.69 year-on-year[23]. - The net cash flow from operating activities surged by 202.94% to CNY 120,294,568.26, compared to CNY 39,709,022.32 in the previous year[23]. - The basic earnings per share increased by 26.01% to CNY 0.1250, up from CNY 0.0992 in the same period last year[23]. - The net profit after deducting non-recurring gains and losses was 35,876,286.87 yuan, reflecting a growth of 28.67% year-on-year[31]. - The company reported a net profit for the first half of 2021 of CNY 49,200,027.29, representing a 26.2% increase from CNY 38,978,093.40 in the first half of 2020[133]. - The total comprehensive income for the first half of 2021 was CNY 73,941,591.99, showing a significant increase compared to the previous period[152]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,690,379,182.94, a decrease of 3.78% from CNY 2,796,099,005.75 at the end of the previous year[23]. - Total liabilities decreased to CNY 547,590,841.81 from CNY 663,864,893.91, a reduction of 17.5%[125]. - Current liabilities totaled CNY 428,116,650.79, down 25.5% from CNY 574,522,426.34[125]. - The equity attributable to shareholders increased to CNY 2,027,160,437.49 from CNY 1,995,717,937.63, an increase of 1.8%[126]. - The total liabilities and equity at the end of the current period amount to 2,080,200,000, consistent with the company's financial structure[150]. Revenue Breakdown - The pharmaceutical sector generated ¥333,043,864.57, accounting for 73.21% of total revenue, with a year-on-year growth of 7.96%[46]. - Revenue from the health food sector surged by 93.39% to ¥44,378,842.73, primarily driven by increased sales of ginseng products[48]. - The cosmetics sector reported revenue of ¥74,717,896.59, reflecting an 18.73% increase from the previous year[46]. - Capsule products contributed ¥215,621,692.51, making up 47.40% of total revenue, with a growth of 7.66% year-on-year[47]. Research and Development - The company has developed a complete ginseng industry chain, expanding from pharmaceutical products to health foods and cosmetics[32]. - The company has registered over 500 cosmetic products, leveraging its ginseng resources and technology[35]. - The company reported a significant increase in R&D investment, which increased by 38.13% to CNY 21,152,443.12, primarily due to higher clinical trial costs[43]. - The company has published 206 academic papers, including 21 indexed by SCI and 42 RCT clinical trial papers, highlighting its commitment to research[36]. Operational Risks - The company faced various operational risks, which are detailed in the report, and it is advised that investors pay attention to these risks[6]. - The company faces risks related to industry policy adjustments, including increased regulatory scrutiny and changes in drug approval processes[58]. - The company faces risks of rising production costs due to increased prices of raw materials, labor, and logistics[60]. - There is a risk of drug price declines as a result of stricter healthcare cost control measures and policies affecting drug pricing mechanisms[60]. Corporate Governance and Social Responsibility - The company emphasizes the protection of shareholder and creditor rights through improved governance and timely information disclosure[72]. - The company actively participates in social responsibility initiatives, contributing to community development and environmental sustainability[72]. - The company has been recognized as a "Contract-abiding and Trustworthy Enterprise" for several consecutive years by the Administration for Industry and Commerce[73]. - The company prioritizes employee rights and well-being, providing social insurance and opportunities for professional development[72]. Shareholder Information - The total number of shares remained unchanged at 330,951,600, with a slight decrease in restricted shares from 99,231,016 to 98,676,111[102]. - Zhang Yisheng holds 39.08% of the shares, totaling 129,348,530 shares, with no changes during the reporting period[107]. - Liu Jianming's shareholding decreased by 40,000 shares, holding 12,831,403 shares, representing 3.88%[107]. - The company has not conducted any repurchase transactions among the top 10 shareholders during the reporting period[108]. Environmental Compliance - The company has established a comprehensive environmental management system and emergency response plan to handle potential environmental incidents[70]. - The company has not faced any administrative penalties for environmental issues during the reporting period, indicating compliance with environmental regulations[69]. - The company actively invested in environmental protection and energy conservation, adhering to relevant environmental regulations for waste management[73]. Accounting and Financial Reporting - The financial statements are prepared based on the accrual basis of accounting, in accordance with the relevant accounting standards[160]. - The company uses RMB as its functional currency for accounting purposes[166]. - The financial report complies with the requirements of the accounting standards, reflecting the group's financial position and operating results accurately[163]. - The company recognizes foreign currency cash flows using the spot exchange rate on the transaction date, with adjustments for exchange rate fluctuations reported separately in the cash flow statement[179].

Financial Performance - The company's operating revenue for Q1 2021 was ¥229,097,736.43, representing a 14.31% increase compared to ¥200,410,031.97 in the same period last year[8]. - Net profit attributable to shareholders for Q1 2021 was ¥27,765,054.54, up 29.24% from ¥21,483,641.33 in the previous year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥23,405,772.17, reflecting a 40.73% increase from ¥16,632,110.71 year-on-year[8]. - The basic earnings per share for Q1 2021 was ¥0.0839, a 29.28% increase from ¥0.0649 in the same period last year[8]. - The company achieved operating revenue of CNY 229,097,736.43, a year-on-year increase of 14.31%[18]. - Net profit attributable to shareholders reached CNY 27,765,054.54, up 29.24% compared to the same period last year[18]. - The total profit for the first quarter was CNY 39,024,730.06, an increase from CNY 29,813,960.90 year-over-year[42]. - The company reported a significant increase in operating profit, which was CNY 41,911,932.69, compared to CNY 31,513,381.89 in the previous year[42]. - Net profit for Q1 2021 increased to CNY 34,668,779.18, compared to CNY 26,187,829.40 in the same period last year[40]. - The total comprehensive income for the first quarter was CNY 33,186,719.33, compared to CNY 25,202,056.45 in the same period last year[42]. Cash Flow - The net cash flow from operating activities was ¥29,363,113.24, a decrease of 7.44% compared to ¥31,724,684.07 in the previous year[8]. - Cash flow from tax refunds increased by 63.62% to CNY 309,038.42, due to higher VAT refunds received[18]. - Total cash inflow from operating activities was ¥245,212,053.73, up from ¥236,143,130.92 in the previous year, reflecting a growth of 4.5%[49]. - Cash outflow from operating activities totaled ¥215,848,940.49, compared to ¥204,418,446.85 in the same period last year, indicating an increase of 5.5%[49]. - The company reported a net cash flow from investing activities of -¥13,880,051.32, worsening from -¥3,085,989.58 in Q1 2020[50]. - Cash inflow from financing activities was ¥50,000,000.00, down from ¥110,000,000.00 in the previous year, representing a decline of 54.5%[50]. - The net cash flow from financing activities was -¥12,241,385.43, compared to -¥2,899,569.82 in Q1 2020, indicating a significant increase in cash outflow[50]. - The ending balance of cash and cash equivalents was ¥290,238,191.42, an increase from ¥88,753,739.80 at the end of Q1 2020[50]. - The net increase in cash and cash equivalents for the period was ¥3,241,676.49, compared to an increase of ¥25,739,124.67 in Q1 2020[50]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,768,818,814.32, down 0.98% from ¥2,796,099,005.75 at the end of the previous year[8]. - The net assets attributable to shareholders at the end of the reporting period were ¥2,023,482,992.17, an increase of 1.39% from ¥1,995,717,937.63 at the end of the previous year[8]. - Total assets as of March 31, 2021, amounted to CNY 2,809,491,036.17, compared to CNY 2,795,950,343.62 at the end of 2020[36]. - Total liabilities decreased to CNY 804,389,575.74 from CNY 853,772,344.48 at the end of 2020[37]. - The company's equity increased to CNY 2,005,101,460.43 from CNY 1,942,177,999.14 at the end of 2020[37]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,899[12]. - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[12]. Expenses - Management expenses rose by 24.15% to CNY 24,930,308.88, attributed to increased employee insurance and salary costs[18]. - Financial expenses decreased by 55.55% to CNY 1,314,678.47, mainly due to increased interest from agreement deposits[18]. - Research and development expenses for Q1 2021 were CNY 4,823,806.99, compared to CNY 4,295,439.68 in the previous period[40]. - The company incurred financial expenses of CNY 2,503,292.90, down from CNY 4,483,604.94 in the previous year[44]. - Research and development expenses for the first quarter were CNY 3,643,031.48, compared to CNY 3,472,786.86 in the previous year[44].

Financial Performance - The company's operating revenue for 2020 was ¥842,589,907.04, a decrease of 16.80% compared to ¥1,012,748,483.99 in 2019[18] - The net profit attributable to shareholders for 2020 was ¥80,060,085.80, representing an increase of 4.52% from ¥76,598,736.73 in 2019[18] - The basic earnings per share for 2020 was ¥0.2419, up 4.54% from ¥0.2314 in 2019[18] - The total assets at the end of 2020 were ¥2,796,099,005.75, reflecting a 12.00% increase from ¥2,496,513,671.23 at the end of 2019[18] - The net assets attributable to shareholders at the end of 2020 were ¥1,995,717,937.63, a 3.29% increase from ¥1,932,205,431.83 at the end of 2019[18] - The net cash flow from operating activities for 2020 was ¥203,514,966.83, a decrease of 3.49% from ¥210,871,994.83 in 2019[18] - The company reported a weighted average return on equity of 4.08% for 2020, slightly up from 4.04% in 2019[18] - The net profit after deducting non-recurring gains and losses for 2020 was ¥65,746,181.53, an increase of 3.15% from ¥63,736,372.05 in 2019[18] - The total revenue for 2020 was ¥842,589,907.04, a decrease of 16.80% compared to ¥1,012,748,483.99 in 2019[49] - The pharmaceutical industry generated ¥642,748,349.58, accounting for 76.28% of total revenue, down 11.42% from the previous year[49] - The cosmetics sector saw a significant decline, with revenue of ¥115,960,117.33, representing a 37.88% drop from ¥186,669,072.67 in 2019[49] Dividend Distribution - The company plans to distribute a cash dividend of ¥0.30 per 10 shares, based on a total of 330,951,600 shares[6] - The cash dividend for 2020 represents 12.40% of the net profit attributable to the company's ordinary shareholders, which was ¥80,060,085.80[93] - In 2019, the company distributed a cash dividend of ¥0.50 per share, totaling ¥16,547,580.00, which accounted for 21.60% of the net profit attributable to ordinary shareholders[93] - The company did not distribute any cash dividends for the year 2018 due to the need for significant funding for future investments and operations[91] - The total undistributed profits at the end of the reporting period amounted to ¥669,928,871.12[93] - The company has established a three-year shareholder return plan to ensure a stable dividend policy[89] Market and Industry Position - The company faces risks including industry policy adjustments, rising production costs, and talent shortages, which may impact future performance[6] - The company is positioned in a weak cyclical industry with strong defensive characteristics, showing resilience against macroeconomic fluctuations[35] - The health industry in China is projected to reach a market value of 16 trillion yuan by 2030, indicating significant growth potential for the company[34] - The company has a strong supply chain advantage, integrating upstream and downstream operations in the ginseng industry, enhancing its competitive edge[37] - The company aims to solidify its position as a leading enterprise in the ginseng industry by expanding its product offerings and market reach[82] Research and Development - The company completed clinical studies for new products, including Zhenyuan capsules for diabetes and XinYue capsules for myocardial energy metabolism[62] - Total R&D investment was ¥33,226,923.58, accounting for 3.94% of operating revenue, an increase of 0.43% from the previous year[62] - The company launched 18 new food products and completed certifications for 8 categories of food production licenses during the reporting period[43] - The company has developed 11 types of dosage forms that have obtained national GMP certification, with 117 varieties and 130 drug approval numbers[27] - The company has received 11 national invention patents related to ginseng cultivation techniques[28] - New product development will focus on market-oriented projects, enhancing competitiveness through improved quality and efficacy of existing products[82] Operational Challenges - The cosmetics segment faced significant challenges due to COVID-19, leading to a shift towards online sales channels, including the launch of a new online shopping platform[45] - Sales expenses decreased by 21.45% to ¥402,566,968.04 due to adjustments in marketing policies and the impact of COVID-19 on sales revenue[61] - R&D expenses decreased by 19.31% to ¥15,711,256.37, reflecting a focus on optimizing product pipelines and innovation[61] - The company reported a significant reduction in inventory levels, with a decrease of 41.45% to 3,959,917 boxes compared to the previous year[53] Corporate Governance - The company has established a performance evaluation system linking employee salaries to company performance and individual contributions[160] - The board of directors consists of nine members, including three independent directors, and operates in compliance with relevant laws and regulations[165] - The company maintains a transparent information disclosure system, ensuring timely and accurate communication with all investors[166] - The independent directors attended all board meetings and shareholder meetings, demonstrating their commitment to corporate governance[172] - The company has established a mechanism for evaluating and incentivizing senior management, ensuring accountability and performance alignment[178] Social Responsibility - The company emphasizes employee rights protection and adheres to labor laws, ensuring a harmonious labor relationship and providing various social insurances[122] - The company actively participates in social welfare initiatives, focusing on tax compliance and support for vulnerable groups[123] - The company has been recognized as a "Contract-abiding and Trustworthy Enterprise" by the administration for several consecutive years, reflecting its commitment to social responsibility[123] Financial Management - The company reported a significant increase in intangible assets, which rose to ¥123,411,899.26 in 2020 from ¥54,737,906.41 in 2019, representing an increase of approximately 125%[200] - Cash and cash equivalents surged to ¥286,996,514.93 in 2020, up from ¥63,014,615.13 in 2019, marking an increase of about 355.5%[199] - Short-term borrowings increased to ¥405,402,493.05 in 2020, compared to ¥280,000,000.00 in 2019, reflecting a rise of about 44.8%[200] - The company has established an independent financial department and accounting system, ensuring independent financial decision-making[169] Shareholding Structure - The total number of shares is 330,951,600, with 29.98% being restricted shares and 70.02% being unrestricted shares[131] - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, amounting to 129,348,530 shares[134] - The company has not reported any other shareholders holding more than 10% of shares apart from the identified major shareholders[140] - The company is addressing issues related to shareholding representation and has implemented a plan to reduce the shares held by proxy shareholders[136]

Financial Performance - Operating revenue for the reporting period was ¥217,121,787.36, a decrease of 9.74% year-on-year, while year-to-date revenue was ¥614,016,426.03, down 17.68% compared to the same period last year[9] - Net profit attributable to shareholders for the reporting period was ¥21,344,867.38, an increase of 39.86% year-on-year, with year-to-date net profit at ¥54,188,768.07, a slight decrease of 2.03%[9] - Basic earnings per share for the reporting period were ¥0.0645, up 39.91% year-on-year, with diluted earnings per share also at ¥0.0645[9] - Total operating revenue for the third quarter was CNY 217,121,787.36, a decrease from CNY 240,548,305.91 in the previous period[40] - The total profit for the third quarter was CNY 29,036,243.91, an increase of 55.4% from CNY 18,694,158.23 in the same period last year[42] - The net profit for the third quarter reached CNY 24,811,661.81, representing a 64.4% increase from CNY 15,131,185.24 year-over-year[42] - The company's operating revenue for the third quarter of 2020 was CNY 482.75 million, a decrease of 17% compared to CNY 580.90 million in the same period last year[53] - The net profit attributable to the parent company was CNY 54.19 million, down 2% from CNY 55.31 million year-on-year[51] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,656,227,086.82, an increase of 6.40% compared to the end of the previous year[9] - Total liabilities rose to CNY 551,133,312.55, up from CNY 438,662,072.17, indicating an increase of about 25.6%[34] - Current liabilities totaled CNY 495,421,577.39, compared to CNY 396,009,424.20, marking an increase of approximately 25.1%[34] - Non-current liabilities increased to CNY 55,711,735.16 from CNY 42,652,647.97, representing a growth of about 30.6%[34] - Owner's equity totaled CNY 2,105,093,774.27, up from CNY 2,057,851,599.06, showing an increase of approximately 2.3%[35] - Total assets increased to CNY 2,656,227,086.82 from CNY 2,496,513,671.23, reflecting a growth of approximately 6.4%[35] - Shareholders' equity totaled CNY 2,057,851,599.06, including CNY 330,951,600.00 in share capital and CNY 662,061,469.59 in undistributed profits[67] Cash Flow - The net cash flow from operating activities was ¥41,286,087.37, a significant increase of 391.10% compared to the same period last year, while year-to-date cash flow decreased by 37.04%[9] - Cash flow from operating activities decreased by 37.04% to ¥80,995,109.69 from ¥128,646,977.15, mainly due to reduced cash payments related to operating activities[19] - The net cash flow from operating activities for Q3 2020 was ¥80,995,109.69, a decrease of 37.0% compared to ¥128,646,977.15 in Q3 2019[58] - Total cash inflow from operating activities was ¥698,939,437.12, down 19.6% from ¥869,039,329.29 in the previous year[58] - Cash outflow from operating activities totaled ¥617,944,327.43, a decrease of 16.5% compared to ¥740,392,352.14 in Q3 2019[58] - The net cash flow from investing activities was -¥5,049,230.35, compared to -¥15,296,426.17 in the same period last year, indicating an improvement[59] - Cash inflow from financing activities was ¥485,000,000.00, an increase of 50.4% from ¥322,550,000.00 in Q3 2019[59] - The net cash flow from financing activities was ¥99,539,423.01, compared to -¥90,838,686.33 in the previous year, showing a significant turnaround[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,486[13] - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[13] - The company has not conducted any repurchase transactions among the top 10 shareholders during the reporting period[14] Government Subsidies and Investments - Other income surged by 140.17% to ¥17,864,094.02 from ¥7,438,032.81, primarily due to increased government subsidies received[19] - The company received a total of ¥7,196,800 in government subsidies from January 1 to April 13, 2020, and ¥15,680,700 from April 13 to August 18, 2020[21] - The company plans to invest ¥344,790,000 in the construction of a ginseng deep processing industry project, requiring 223.5 acres of land[21] Expenses - The company reported a significant increase in financial expenses, which decreased by 41.28% to ¥7,715,363.07 from ¥13,139,246.29, due to a reduction in the average balance of short-term borrowings[19] - Research and development expenses decreased to CNY 5,413,750.43, a reduction of 24.6% compared to CNY 7,187,456.00 in the previous year[41] - Sales expenses for the third quarter were CNY 108,494,192.12, down 15.9% from CNY 128,943,551.63 year-over-year[41] - The income tax expense for the quarter was CNY 10.48 million, compared to CNY 12.33 million in the same period last year, reflecting a decrease of about 15%[50] Other Financial Metrics - The weighted average return on net assets was 1.09%, an increase from 0.29% in the previous year[9] - The company reported a credit impairment loss of CNY -496,729.74, significantly improved from CNY -6,292,297.70 in the previous year[41] - The company reported a credit impairment loss of CNY -4.43 million, an improvement from CNY -7.39 million in the previous year[50] - The total comprehensive income for the third quarter was CNY 24,811,661.81, compared to CNY 15,131,185.24 in the same period last year, reflecting a growth of 64.4%[43] - The total comprehensive income for the third quarter was CNY 63.79 million, down from CNY 68.31 million year-on-year[51]

1 证券代码：002566 证券简称：益盛药业 公告编号：2020-029 吉林省集安益盛药业股份有限公司 关于投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，吉林省集安益盛药业股份有限公司（以 下简称"公司"）将参加由吉林证监局、吉林省证券业协会、深圳市全景网络有 限公司共同举办的"提高公司质量 做受尊敬的上市公司--2020年吉林辖区上市 公司投资者网上集体接待日"活动，现将有关事项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆"全景•路演天下"网站（http://rs.p5w.net）参与公司本 次投资者集体接待日活动,时间为2020年8月21日（周五）15:30至17:00。 届时公司总经理薛晓民先生、董事会秘书丁富君先生、财务总监毕建涛先生， 将通过网络在线问答互动的形式，与投资者就公司治理、发展经营情况和可持续 发展等投资者关注的问题进行交流。期间，公司高管将全程在线，实时回答投资 者的提问。 欢迎广大投资者积极参与。 特此公告。 吉 ...